FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:432-433 July 28, 2005 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Van Assche, G. Related Article by Kleinschmidt-DeMasters, B.K. Related Article by Langer-Gould, A. PubMed Citation

The Brief Reports on natalizumab were referred to Biogen Idec, the manufacturer, which offers the following response: After learning of one confirmed and one suspected case of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab, Biogen Idec and Elan quickly notified the Food and Drug Administration (FDA) and other regulatory authorities. We worked closely with the FDA to understand the significance of these findings and to determine the appropriate action. On February 28, we voluntarily suspended all dosing and marketing of natalizumab; swift and decisive action was guided by our commitment to patient safety. Immediate efforts also included a . . . [Full Text of this Article]

Related Letters:

Antibody to ₄₇ Integrin for Ulcerative Colitis
Danese S., De La Rue S. A., Gasbarrini A., Feagan B. G., Fox I. H., Kishimoto K.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1180-1181, Sep 15, 2005. Correspondence

This article has been cited by other articles:

• Kaneko, S., Wang, J., Kaneko, M., Yiu, G., Hurrell, J. M., Chitnis, T., Khoury, S. J., He, Z. (2006). Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models.. J. Neurosci. 26: 9794-9804 [Abstract] [Full Text]  
• Kerfoot, S. M., Norman, M. U., Lapointe, B. M., Bonder, C. S., Zbytnuik, L., Kubes, P. (2006). Reevaluation of P-Selectin and {alpha}4 Integrin as Targets for the Treatment of Experimental Autoimmune Encephalomyelitis. J. Immunol. 176: 6225-6234 [Abstract] [Full Text]  
• Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E.-W., Jager, H. R., Clifford, D. B. (2006). Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.. NEJM 354: 924-933 [Abstract] [Full Text]  
• Keeley, K. A, Rivey, M. P, Allington, D. R (2005). Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. The Annals of Pharmacotherapy 39: 1833-1843 [Abstract] [Full Text]  
• Danese, S., De La Rue, S. A., Gasbarrini, A., Feagan, B. G., Fox, I. H., Kishimoto, K. (2005). Antibody to {alpha}4{beta}7 Integrin for Ulcerative Colitis. NEJM 353: 1180-1181 [Full Text]  
• (2005). PML in Patients Receiving Natalizumab. JWatch Infect. Diseases 2005: 1-1 [Full Text]